Iterum Therapeutics (ITRM) has received a Nasdaq determination to delist its ordinary shares due to noncompliance with the $1.00 bid price rule and the $35 million market value standard. Trading is scheduled to be suspended on March 5, 2026, unless the company requests a hearing. The company also remains out of compliance with related equity and net income requirements.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Iterum Therapeutics Received Notice of Delisting
Iterum Therapeutics (ITRM) has received a Nasdaq determination to delist its ordinary shares due to noncompliance with the $1.00 bid price rule and the $35 million market value standard. Trading is scheduled to be suspended on March 5, 2026, unless the company requests a hearing. The company also remains out of compliance with related equity and net income requirements.